Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
OPC1 · 1 trial · 5 indications
Frequency and severity of the MI PSD System or injection procedure related adverse events (AEs) through 30 days (1 month).
| Arm | Type | Description |
|---|---|---|
| LCTOPC1 | EXPERIMENTAL | Open Label Single Injection of LCTOPC1 at a Single Time Point |
| Name | Type | Description |
|---|---|---|
| OPC1 | BIOLOGICAL | One injection of 10 million LCTOPC1 cells will be delivered to the target injection site of the damaged spinal tissue. |
Inclusion Criteria: 1. Sensorimotor complete, traumatic SCI (ASIA Impairment Scale A) or sensory incomplete, traumatic SCI (ASIA Impairment Scale B) 2. For subjects with subacute injury, International Standards for Neurological Classification of SCI (ISNCSCI) Neurological Level of Injury (NLI) from...
OPC1 is an investigational cell therapy being developed for spinal cord injury, specifically cervical spinal cord injury. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
OPC1 is being developed by Lineage Cell Therapeutics, Inc., a biopharmaceutical company traded on the NYSE American under the ticker symbol LCTX.
OPC1 is in Phase 1 clinical development. It is an investigational product and has not received regulatory approval. A Phase 1 trial is currently recruiting participants.
OPC1 is being studied in a Phase 1 clinical trial with the identifier NCT06841770. This trial is evaluating the safety of a delivery device for administering LCTOPC1 in participants with spinal cord injury, including cervical and thoracic spinal cord injury.
Yes, OPC1 is also known as LCTOPC1. The clinical trial NCT06841770 refers to the product as LCTOPC1, which is the same investigational cell therapy being developed by Lineage Cell Therapeutics.